Arcellx Inc. (ACLX), which reported positive preliminary data from its pivotal iMMagine-1 study in May of this year, is scheduled to present updated data next month.
The iMMagine-1 is a phase 2 study evaluating the company's lead investigational product, Anitocabtagene autoleucel (anito-cel), in patients with relapsed or refractory multiple myeloma. Anito-cel is an autologous anti-B-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR) T-cell therapy that belongs to the same class as Johnson & Johnson/Legend's Carvykti and Bristol Myers Squibb's Abecma, which are approved for relapsed or refractory (R/R) multiple myeloma (MM).
For comments and feedback contact: editorial@rttnews.com
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.